A US governmental advisory committee is critically looking at inhaled type of insulin which is designed to aid millions of diabetes sufferers who currently depend on injecting to control blood sugar.

The main concern with regards to the drug is its long-term effects on the lungs and whether it is safe and effective for smokers or those who have lung disease, so says documents released by the US Food and Drug Administration.

The inhaled insulin is called Exubera and could help diabetics who do not want to inject. The insulin is being developed by Pfizer, Sanofi-Aventis and Nektar Therapeutics.

The FDA was to consider today whether to recommend the drug to government regulators for approval. The FDA usually follows the recommendations of its advisory committees, but is not required to.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…